TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Naltrexone in the Treatment of Dissociative Symptoms in Patients With Borderline Personality Disorder
Brief Summary: Our study aims at contributing to a valid appraisal of the magnitude of naltrexone efficacy as an antidissociative agent by using a double-blind randomized controlled trial.


Options:
A: Arm Label: Intensive Group Analytic Psychotherapy; Type: EXPERIMENTAL; Interventions: Behavioral: Intensive Group Analytic Psychotherapy | Arm Label: Intensive GCBT; Type: EXPERIMENTAL; Interventions: Behavioral: Intensive transdiagnostic cognitive-behavioral group therapy | Arm Label: Wait-list control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Intensive Group Analytic Psychotherapy; Assigned to Arm(s): Intensive Group Analytic Psychotherapy | Intervention Type: BEHAVIORAL; Name: Intensive transdiagnostic cognitive-behavioral group therapy; Assigned to Arm(s): Intensive GCBT
B: Arm Label: Naltrexone-Placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Naltrexone, Drug: Placebo | Arm Label: Placebo-Naltrexone; Type: PLACEBO_COMPARATOR; Interventions: Drug: Naltrexone, Drug: Placebo | Intervention Type: DRUG; Name: Naltrexone; Assigned to Arm(s): Naltrexone-Placebo, Placebo-Naltrexone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Naltrexone-Placebo, Placebo-Naltrexone
C: Arm Label: dynamic deconstructive psychotherapy; Type: EXPERIMENTAL; Interventions: Behavioral: Psychodynamic Therapy | Arm Label: optimized community care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Optimized Community Care | Intervention Type: BEHAVIORAL; Name: Psychodynamic Therapy; Assigned to Arm(s): dynamic deconstructive psychotherapy | Intervention Type: BEHAVIORAL; Name: Optimized Community Care; Assigned to Arm(s): optimized community care
D: Arm Label: Mindfulness skills; Type: EXPERIMENTAL; Interventions: Behavioral: Mindfulness skills training | Arm Label: Interpersonal effectiveness skills; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Interpersonal Effectiveness skills training | Intervention Type: BEHAVIORAL; Name: Mindfulness skills training; Assigned to Arm(s): Mindfulness skills | Intervention Type: BEHAVIORAL; Name: Interpersonal Effectiveness skills training; Assigned to Arm(s): Interpersonal effectiveness skills

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The VISION STUDY: Variation In Success of Intravenous (IV) Placement With Observation Using New Techniques
Brief Summary: Children fear having an intravenous (IV) needle placed because of the pain that they will experience. The more needle punctures that a child has to endure before the IV is successfully placed, the greater the pain experienced and anxiety suffered. In addition, false starts increase the demands on medical staff and can increase the length of the emergency department stay. Often, veins are difficult to see or feel, particularly in an unwell, dehydrated child or in young infants who have more fat below the skin surface. Also, the venous pattern below the skin surface naturally varies from person to person and therefore success in placing IVs leaves room for improvement. Technology may be able to play an important role is improving the rates of success. The investigators wish to investigate whether the use of either an Ultrasound machine or a VeinViewer machine can improve the rate of success of the initial attempt (skin puncture) at peripheral IV placement in comparison to the current standard approach.


Options:
A: Arm Label: VeinViewer; Type: ACTIVE_COMPARATOR; Interventions: Device: Veinviewer | Arm Label: Ultrasound; Type: ACTIVE_COMPARATOR; Interventions: Device: Ultrasound | Arm Label: Conventional IV placement; Type: ACTIVE_COMPARATOR; Interventions: Other: Conventional technique | Intervention Type: DEVICE; Name: Veinviewer; Assigned to Arm(s): VeinViewer | Intervention Type: DEVICE; Name: Ultrasound; Assigned to Arm(s): Ultrasound | Intervention Type: OTHER; Name: Conventional technique; Assigned to Arm(s): Conventional IV placement
B: Arm Label: Grade 1 Vein Visualization; Type: OTHER; Interventions: Other: IV placement using ultrasound guidance vs traditional method | Arm Label: Grade 2A Vein Visualization; Type: OTHER; Interventions: Other: IV placement using ultrasound guidance vs traditional method | Arm Label: Grade 2b Vein Visualization; Type: OTHER; Interventions: Other: IV placement using ultrasound guidance vs traditional method | Arm Label: Grade 3 Vein Visualization; Type: OTHER; Interventions: Other: IV placement using ultrasound guidance vs traditional method | Intervention Type: OTHER; Name: IV placement using ultrasound guidance vs traditional method; Assigned to Arm(s): Grade 1 Vein Visualization, Grade 2A Vein Visualization, Grade 2b Vein Visualization, Grade 3 Vein Visualization
C: Arm Label: Ultrasound-guided peripheral IV.; Type: EXPERIMENTAL; Interventions: Device: Ultrasound | Arm Label: Traditional landmark technique; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Ultrasound; Assigned to Arm(s): Ultrasound-guided peripheral IV.
D: Arm Label: one intervention arm; Type: EXPERIMENTAL; Interventions: Procedure: peripheral venous puncture | Intervention Type: PROCEDURE; Name: peripheral venous puncture; Assigned to Arm(s): one intervention arm

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Selection of Chemoradiotherapy Based on Response to Induction Chemotherapy - a Phase II Study in Locally Advanced Squamous Cell Carcinoma of Head and Neck
Brief Summary: Primary

Compare response rates (relative change in tumor size) to induction chemotherapy consisting of cisplatin/paclitaxel/cetuximab +/- everolimus.

Secondary:

Determine the maximum administered dose (MAD), maximum tolerated dose (MTD), dose limiting toxicity (DLT), and safety of everolimus with cisplatin/paclitaxel/cetuximab induction chemotherapy (phase I portion)


Options:
A: Intervention Type: DRUG; Name: cisplatin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: docetaxel; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: fluorouracil; Assigned to Arm(s): N/A | Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): N/A
B: Arm Label: Docetaxel Cisplatin 5-Fluorouracil (DCF); Type: EXPERIMENTAL; Interventions: Drug: DOCETAXEL, Drug: CISPLATIN, Drug: 5-FLUOROURACIL | Arm Label: Cisplatin 5-Fluorouracil (CF); Type: EXPERIMENTAL; Interventions: Drug: CISPLATIN, Drug: 5-FLUOROURACIL | Intervention Type: DRUG; Name: DOCETAXEL; Assigned to Arm(s): Docetaxel Cisplatin 5-Fluorouracil (DCF) | Intervention Type: DRUG; Name: CISPLATIN; Assigned to Arm(s): Cisplatin 5-Fluorouracil (CF), Docetaxel Cisplatin 5-Fluorouracil (DCF) | Intervention Type: DRUG; Name: 5-FLUOROURACIL; Assigned to Arm(s): Cisplatin 5-Fluorouracil (CF), Docetaxel Cisplatin 5-Fluorouracil (DCF)
C: Arm Label: Cabazitaxel; Type: EXPERIMENTAL; Interventions: Drug: Cabazitaxel | Arm Label: Methotrexate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methotrexate | Intervention Type: DRUG; Name: Cabazitaxel; Assigned to Arm(s): Cabazitaxel | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): Methotrexate
D: Arm Label: Everolimus; Type: EXPERIMENTAL; Interventions: Drug: Everolimus | Arm Label: Placebo; Type: EXPERIMENTAL; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): Everolimus | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: HZA106829: A Randomised, Double-blind, Parallel Group, Multicentre Study of Fluticasone Furoate/GW642444 Inhalation Powder, Fluticasone Furoate Inhalation Powder Alone, and Fluticasone Propionate Alone in the Treatment of Persistent Asthma in Adults and Adolescents
Brief Summary: The purpose of the study is to compare the efficacy and safety of fluticasone furoate/vilanterol (GW642444) inhalation powder administered once daily each evening with fluticasone furoate inhalation powder administered alone once daily each evening in adolescent and adult subjects 12 years of age and older with persistent bronchial asthma over a 24-week period.


Options:
A: Intervention Type: DRUG; Name: FLUTIFORM® (Formoterol fumarate / Fluticasone propionate); Assigned to Arm(s): N/A
B: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: tiotropium low dose | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: tiotropium high dose | Arm Label: C; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: tiotropium high dose; Assigned to Arm(s): B | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): C | Intervention Type: DRUG; Name: tiotropium low dose; Assigned to Arm(s): A
C: Arm Label: Foster® NEXThaler®; Type: EXPERIMENTAL; Interventions: Drug: Foster® NEXThaler® 100/6 µg/unit dose | Arm Label: Seretide® Accuhaler®; Type: ACTIVE_COMPARATOR; Interventions: Drug: Seretide® Accuhaler® 250/50 µg/actuation | Intervention Type: DRUG; Name: Foster® NEXThaler® 100/6 µg/unit dose; Assigned to Arm(s): Foster® NEXThaler® | Intervention Type: DRUG; Name: Seretide® Accuhaler® 250/50 µg/actuation; Assigned to Arm(s): Seretide® Accuhaler®
D: Arm Label: Fluticasone Furoate/Vilanterol; Type: EXPERIMENTAL; Interventions: Drug: Fluticasone Furoate/Vilanterol Inhalation Powder, Other: Placebo Inhalation Powder 2 | Arm Label: Fluticasone Furoate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fluticasone Furoate Inhalation Powder, Other: Placebo Inhalation Powder 2 | Arm Label: Fluticasone Propionate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fluticasone Propionate Inhalation Powder, Other: Placebo Inhalation Powder 1 | Intervention Type: DRUG; Name: Fluticasone Furoate/Vilanterol Inhalation Powder; Assigned to Arm(s): Fluticasone Furoate/Vilanterol | Intervention Type: DRUG; Name: Fluticasone Furoate Inhalation Powder; Assigned to Arm(s): Fluticasone Furoate | Intervention Type: DRUG; Name: Fluticasone Propionate Inhalation Powder; Assigned to Arm(s): Fluticasone Propionate | Intervention Type: OTHER; Name: Placebo Inhalation Powder 1; Assigned to Arm(s): Fluticasone Propionate | Intervention Type: OTHER; Name: Placebo Inhalation Powder 2; Assigned to Arm(s): Fluticasone Furoate, Fluticasone Furoate/Vilanterol

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Prospective, Randomized Clinical Study of VELCADE-Thalidomide-Dexamethasone (VTD) Versus Thalidomide-Dexamethasone (TD) for Previously Untreated Multiple Myeloma (MM) Patients Who Are Candidates to Receive Double Autologous Transplantation
Brief Summary: Thalidomide-Dexamethasone (TD) is a standard induction therapy for Multiple Myeloma (MM). The present study is designed to compare TD with VELCADE-Thalidomide-Dexamethasone (VTD) as induction therapy in preparation for, and as consolidation after, melphalan-based double autologous stem cell transplantation for previously untreated patients aged ≤65 years with symptomatic MM. Primary study endpoint is the rate of complete response (CR) plus near-complete response (nCR) to induction treatment. Secondary endpoints include the rate of CR plus nCR to double transplantation and subsequent consolidation therapy, time to progression (TTP), progression-free survival (PFS),overall survival (OS) and toxicity profile of both VTD and TD.


Options:
A: Intervention Type: PROCEDURE; Name: autologous PBSC transplant; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: Alternating chemotherapy; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: Autologous Transplantation; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Maintenance; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: Second transplantation; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: ALOGENIC MINI TRASPLANTATION; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: Velcade; Assigned to Arm(s): N/A
D: Arm Label: VTD; Type: EXPERIMENTAL; Interventions: Drug: Velcade, Drug: Thalidomide, Drug: Dexamethasone, Procedure: Peripheral Blood Stem Cell (PBSC) collection, Procedure: First Autologous Transplantation, Procedure: Second Autologous Transplantation | Arm Label: TD; Type: ACTIVE_COMPARATOR; Interventions: Drug: Thalidomide, Drug: Dexamethasone, Procedure: Peripheral Blood Stem Cell (PBSC) collection, Procedure: First Autologous Transplantation, Procedure: Second Autologous Transplantation | Intervention Type: DRUG; Name: Velcade; Assigned to Arm(s): VTD | Intervention Type: DRUG; Name: Thalidomide; Assigned to Arm(s): TD, VTD | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): TD, VTD | Intervention Type: PROCEDURE; Name: Peripheral Blood Stem Cell (PBSC) collection; Assigned to Arm(s): TD, VTD | Intervention Type: PROCEDURE; Name: First Autologous Transplantation; Assigned to Arm(s): TD, VTD | Intervention Type: PROCEDURE; Name: Second Autologous Transplantation; Assigned to Arm(s): TD, VTD

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Prospective, Randomized Clinical Study of VELCADE-Thalidomide-Dexamethasone (VTD) Versus Thalidomide-Dexamethasone (TD) for Previously Untreated Multiple Myeloma (MM) Patients Who Are Candidates to Receive Double Autologous Transplantation
Brief Summary: Thalidomide-Dexamethasone (TD) is a standard induction therapy for Multiple Myeloma (MM). The present study is designed to compare TD with VELCADE-Thalidomide-Dexamethasone (VTD) as induction therapy in preparation for, and as consolidation after, melphalan-based double autologous stem cell transplantation for previously untreated patients aged ≤65 years with symptomatic MM. Primary study endpoint is the rate of complete response (CR) plus near-complete response (nCR) to induction treatment. Secondary endpoints include the rate of CR plus nCR to double transplantation and subsequent consolidation therapy, time to progression (TTP), progression-free survival (PFS),overall survival (OS) and toxicity profile of both VTD and TD.


Options:
A: Intervention Type: DRUG; Name: bortezomib; Assigned to Arm(s): N/A
B: Arm Label: VTD; Type: EXPERIMENTAL; Interventions: Drug: Velcade, Drug: Thalidomide, Drug: Dexamethasone, Procedure: Peripheral Blood Stem Cell (PBSC) collection, Procedure: First Autologous Transplantation, Procedure: Second Autologous Transplantation | Arm Label: TD; Type: ACTIVE_COMPARATOR; Interventions: Drug: Thalidomide, Drug: Dexamethasone, Procedure: Peripheral Blood Stem Cell (PBSC) collection, Procedure: First Autologous Transplantation, Procedure: Second Autologous Transplantation | Intervention Type: DRUG; Name: Velcade; Assigned to Arm(s): VTD | Intervention Type: DRUG; Name: Thalidomide; Assigned to Arm(s): TD, VTD | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): TD, VTD | Intervention Type: PROCEDURE; Name: Peripheral Blood Stem Cell (PBSC) collection; Assigned to Arm(s): TD, VTD | Intervention Type: PROCEDURE; Name: First Autologous Transplantation; Assigned to Arm(s): TD, VTD | Intervention Type: PROCEDURE; Name: Second Autologous Transplantation; Assigned to Arm(s): TD, VTD
C: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: VBMCP/VBAD/Velcade | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: Thalidomide/Dexamethasone | Arm Label: C; Type: EXPERIMENTAL; Interventions: Drug: Velcade/Thalidomide/Dexamethasone | Intervention Type: DRUG; Name: VBMCP/VBAD/Velcade; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Thalidomide/Dexamethasone; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Velcade/Thalidomide/Dexamethasone; Assigned to Arm(s): C
D: Arm Label: No treatment; Type: ACTIVE_COMPARATOR; Interventions: Drug: bortezomib | Arm Label: Bortezomib consolidation; Type: EXPERIMENTAL; Interventions: Drug: bortezomib | Intervention Type: DRUG; Name: bortezomib; Assigned to Arm(s): Bortezomib consolidation, No treatment

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II Trial of GM-CSF Protein Plus Ipilimumab in Patients With Advanced Melanoma
Brief Summary: This randomized phase II trial is studying how well giving ipilimumab with or without sargramostim (GM-CSF) works in treating patients with stage III or stage IV melanoma that cannot be removed by surgery (unresectable). Ipilimumab works by activating the patient's immune system to fight cancer. Colony-stimulating factors, such as sargramostim, may increase the number of immune cells found in bone marrow or peripheral blood and may help the immune system recover from the side effects of treatment. It is not yet known whether giving ipilimumab together with sargramostim is more effective than ipilimumab alone in treating melanoma.


Options:
A: Arm Label: Vemurafenib; Type: EXPERIMENTAL; Interventions: Drug: Vemurafenib | Arm Label: Dacarbazine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dacarbazine | Intervention Type: DRUG; Name: Vemurafenib; Assigned to Arm(s): Vemurafenib | Intervention Type: DRUG; Name: Dacarbazine; Assigned to Arm(s): Dacarbazine
B: Arm Label: Arm A (ipilimumab and sargramostim); Type: EXPERIMENTAL; Interventions: Biological: Ipilimumab, Biological: Sargramostim | Arm Label: Arm B (ipilimumab); Type: ACTIVE_COMPARATOR; Interventions: Biological: Ipilimumab | Intervention Type: BIOLOGICAL; Name: Ipilimumab; Assigned to Arm(s): Arm A (ipilimumab and sargramostim), Arm B (ipilimumab) | Intervention Type: BIOLOGICAL; Name: Sargramostim; Assigned to Arm(s): Arm A (ipilimumab and sargramostim)
C: Arm Label: Ipilimumab and Placebo matching Nivolumab; Type: EXPERIMENTAL; Interventions: Drug: Ipilimumab, Other: Placebo matching Nivolumab | Arm Label: Nivolumab and Placebo matching Ipilimumab; Type: EXPERIMENTAL; Interventions: Drug: Nivolumab, Other: Placebo matching Ipilimumab | Intervention Type: DRUG; Name: Ipilimumab; Assigned to Arm(s): Ipilimumab and Placebo matching Nivolumab | Intervention Type: DRUG; Name: Nivolumab; Assigned to Arm(s): Nivolumab and Placebo matching Ipilimumab | Intervention Type: OTHER; Name: Placebo matching Ipilimumab; Assigned to Arm(s): Nivolumab and Placebo matching Ipilimumab | Intervention Type: OTHER; Name: Placebo matching Nivolumab; Assigned to Arm(s): Ipilimumab and Placebo matching Nivolumab
D: Arm Label: Pembrolizumab; Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Pembrolizumab, Other: Placebo | Intervention Type: BIOLOGICAL; Name: Pembrolizumab; Assigned to Arm(s): Pembrolizumab, Placebo | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II Trial of GM-CSF Protein Plus Ipilimumab in Patients With Advanced Melanoma
Brief Summary: This randomized phase II trial is studying how well giving ipilimumab with or without sargramostim (GM-CSF) works in treating patients with stage III or stage IV melanoma that cannot be removed by surgery (unresectable). Ipilimumab works by activating the patient's immune system to fight cancer. Colony-stimulating factors, such as sargramostim, may increase the number of immune cells found in bone marrow or peripheral blood and may help the immune system recover from the side effects of treatment. It is not yet known whether giving ipilimumab together with sargramostim is more effective than ipilimumab alone in treating melanoma.


Options:
A: Arm Label: Vemurafenib, pill, twice daily; Type: EXPERIMENTAL; Interventions: Drug: Vemurafenib, Drug: Cobimetinib | Intervention Type: DRUG; Name: Vemurafenib; Assigned to Arm(s): Vemurafenib, pill, twice daily | Intervention Type: DRUG; Name: Cobimetinib; Assigned to Arm(s): Vemurafenib, pill, twice daily
B: Arm Label: Dostarlimab (TSR-042) (singly); Type: EXPERIMENTAL; Interventions: Drug: Dostarlimab (TSR-042) (singly) | Arm Label: Dostarlimab (TSR-042) and Cobolimab TSR-022 (combination); Type: EXPERIMENTAL; Interventions: Drug: Dostarlimab (TSR-042) and TSR-022 (combination) | Intervention Type: DRUG; Name: Dostarlimab (TSR-042) (singly); Assigned to Arm(s): Dostarlimab (TSR-042) (singly) | Intervention Type: DRUG; Name: Dostarlimab (TSR-042) and TSR-022 (combination); Assigned to Arm(s): Dostarlimab (TSR-042) and Cobolimab TSR-022 (combination)
C: Arm Label: Arm A: Adjuvant Nivolumab (Complete Pathological Response); Type: ACTIVE_COMPARATOR; Interventions: Drug: nivolumab | Arm Label: Arm B: Adjuvant Nivolumab (Less than Complete Response); Type: ACTIVE_COMPARATOR; Interventions: Drug: nivolumab | Arm Label: Arm C: Adjuvant Combination (Less than Complete Response); Type: EXPERIMENTAL; Interventions: Drug: nivolumab, Drug: Ipilimumab | Intervention Type: DRUG; Name: nivolumab; Assigned to Arm(s): Arm A: Adjuvant Nivolumab (Complete Pathological Response), Arm B: Adjuvant Nivolumab (Less than Complete Response), Arm C: Adjuvant Combination (Less than Complete Response) | Intervention Type: DRUG; Name: Ipilimumab; Assigned to Arm(s): Arm C: Adjuvant Combination (Less than Complete Response)
D: Arm Label: Arm A (ipilimumab and sargramostim); Type: EXPERIMENTAL; Interventions: Biological: Ipilimumab, Biological: Sargramostim | Arm Label: Arm B (ipilimumab); Type: ACTIVE_COMPARATOR; Interventions: Biological: Ipilimumab | Intervention Type: BIOLOGICAL; Name: Ipilimumab; Assigned to Arm(s): Arm A (ipilimumab and sargramostim), Arm B (ipilimumab) | Intervention Type: BIOLOGICAL; Name: Sargramostim; Assigned to Arm(s): Arm A (ipilimumab and sargramostim)

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluating Innovative Weight Reduction Strategies for College Students
Brief Summary: Examine the effectiveness of a weight gain prevention intervention to positively affect body mass index in 2-year college students


Options:
A: Arm Label: Physical activity treatment group; Type: EXPERIMENTAL; Interventions: Behavioral: Pedal@Work | Arm Label: Wait List Control; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Pedal@Work Worksite Wellness | Intervention Type: BEHAVIORAL; Name: Pedal@Work Worksite Wellness; Assigned to Arm(s): Wait List Control | Intervention Type: BEHAVIORAL; Name: Pedal@Work; Assigned to Arm(s): Physical activity treatment group
B: Arm Label: Intervention Group; Type: EXPERIMENTAL; Interventions: Behavioral: CHOICES Intervention | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: CHOICES Intervention; Assigned to Arm(s): Intervention Group
C: Arm Label: Cognitive app; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Mobile Intervention for Lifestyle Eating/Exercise @ Stanford | Arm Label: Social app; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Mobile Intervention for Lifestyle Eating/Exercise @ Stanford | Arm Label: Affect app; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Mobile Intervention for Lifestyle Eating/Exercise @ Stanford | Arm Label: Nutrition app; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Mobile Intervention for Lifestyle Eating/Exercise @ Stanford | Intervention Type: BEHAVIORAL; Name: Mobile Intervention for Lifestyle Eating/Exercise @ Stanford; Assigned to Arm(s): Affect app, Cognitive app, Nutrition app, Social app
D: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: text messages related to sedentary behaviour | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: text messages related to sedentary behaviour; Assigned to Arm(s): Intervention

Answer: B